Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
Radiat Oncol. 2023 Oct 2;18(1):160. doi: 10.1186/s13014-023-02347-9.
In pediatric radiotherapy treatment planning of abdominal tumors, dose constraints to the pancreatic tail/spleen are applied to reduce late toxicity. In this study, an analysis of inter- and intrafraction motion of the pancreatic tail/spleen is performed to estimate the potential benefits of online MRI-guided radiotherapy (MRgRT).
Ten randomly selected neuroblastoma patients (median age: 3.4 years), irradiated with intensity-modulated arc therapy at our department (prescription dose: 21.6/1.8 Gy), were retrospectively evaluated for inter- and intrafraction motion of the pancreatic tail/spleen. Three follow-up MRIs (T2- and T1-weighted ± gadolinium) were rigidly registered to a planning CT (pCT), on the vertebrae around the target volume. The pancreatic tail/spleen were delineated on all MRIs and pCT. Interfraction motion was defined as a center of gravity change between pCT and T2-weighted images in left-right (LR), anterior-posterior (AP) and cranial-caudal (CC) direction. For intrafraction motion analysis, organ position on T1-weighted ± gadolinium was compared to T2-weighted. The clinical radiation plan was used to estimate the dose received by the pancreatic tail/spleen for each position.
The median (IQR) interfraction motion was minimal in LR/AP, and largest in CC direction; pancreatic tail 2.5 mm (8.9), and spleen 0.9 mm (3.9). Intrafraction motion was smaller, but showed a similar motion pattern (pancreatic tail, CC: 0.4 mm (1.6); spleen, CC: 0.9 mm (2.8)). The differences of Dmean associated with inter- and intrafraction motions ranged from - 3.5 to 5.8 Gy for the pancreatic tail and - 1.2 to 3.0 Gy for the spleen. In 6 out of 10 patients, movements of the pancreatic tail and spleen were highlighted as potentially clinically significant because of ≥ 1 Gy dose constraint violation.
Inter- and intrafraction organ motion results into unexpected constrain violations in 60% of a randomly selected neuroblastoma cohort, supporting further prospective exploration of MRgRT.
在儿科腹部肿瘤放射治疗计划中,为了降低迟发性毒性,对胰腺尾部/脾脏施予剂量限制。本研究对胰腺尾部/脾脏的内外运动进行分析,以评估在线磁共振引导放射治疗(MRgRT)的潜在获益。
回顾性分析我院接受强度调制弧形治疗的 10 例神经母细胞瘤患者(中位年龄:3.4 岁)的胰腺尾部/脾脏内外运动。对 3 次随访的磁共振成像(T2 加权和 T1 加权加钆对比剂)与靶区周围椎体的计划 CT(pCT)进行刚性配准。在所有 MRI 和 pCT 上对胰腺尾部/脾脏进行勾画。定义器官在 pCT 和 T2 加权图像之间的质心变化为左右(LR)、前后(AP)和头尾(CC)方向的器官位置变化。对于分次内运动分析,将 T1 加权加钆对比剂与 T2 加权图像进行比较。根据各位置的情况,利用临床放射治疗计划评估胰腺尾部/脾脏的剂量。
LR/AP 方向的器官运动最小,CC 方向的器官运动最大;胰腺尾部 2.5mm(8.9),脾脏 0.9mm(3.9)。分次内运动较小,但运动模式相似(胰腺尾部,CC:0.4mm(1.6);脾脏,CC:0.9mm(2.8))。胰腺尾部和脾脏的 Dmean 与内外运动相关的差异范围分别为-3.5 至 5.8Gy 和-1.2 至 3.0Gy。在 10 例患者中有 6 例,胰腺尾部和脾脏的运动导致≥1Gy 剂量限制的潜在临床显著变化。
60%的随机选择神经母细胞瘤队列中,器官内外运动导致意外的剂量限制违反,支持进一步前瞻性探索 MRgRT。